Cargando…

Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?

INTRODUCTION: A period of exclusivity for the first generics, as part of the patent linkage system, was established in South Korea to provide an economic incentive for early generic entry. This study describes the dynamics of generic penetration and assesses the first mover market share advantages u...

Descripción completa

Detalles Bibliográficos
Autor principal: Son, Kyung-Bok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435867/
https://www.ncbi.nlm.nih.gov/pubmed/37601172
http://dx.doi.org/10.3389/fpubh.2023.1120729
_version_ 1785092201203630080
author Son, Kyung-Bok
author_facet Son, Kyung-Bok
author_sort Son, Kyung-Bok
collection PubMed
description INTRODUCTION: A period of exclusivity for the first generics, as part of the patent linkage system, was established in South Korea to provide an economic incentive for early generic entry. This study describes the dynamics of generic penetration and assesses the first mover market share advantages under the patent linkage system. METHODS: Pairs of originators and their corresponding generics granted the first generic exclusivity from 2015 to 2020 were identified. We categorized generics into first movers and latecomers, described the penetration curves of generics, and estimated the saturated market share of generics, first movers, and latecomers. Volume-based monthly prescriptions were used to describe the generics’ penetration curves. A logistic growth model was adopted to estimate the saturated market shares of generics. RESULTS: We identified 28 pairs of originators and generics, presented penetration curves, and estimated generics market shares. The saturated market share of generics was 30%, and the time to saturation was approximately 33 months. The shapes of penetration varied by nationality, route, and number of generics. The existence of latecomers was associated with the decreased penetration speed over time and decreased market share of generics. However, the first mover market share advantages or latecomers’ disadvantages were consistently observed. CONCLUSION: The generic uptake in South Korea is delayed, limited, and context-dependent. However, first generics’ market share advantage suggests that a period of exclusivity, as part of the patent linkage system, could provide an economic incentive for early generic entrance.
format Online
Article
Text
id pubmed-10435867
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-104358672023-08-19 Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system? Son, Kyung-Bok Front Public Health Public Health INTRODUCTION: A period of exclusivity for the first generics, as part of the patent linkage system, was established in South Korea to provide an economic incentive for early generic entry. This study describes the dynamics of generic penetration and assesses the first mover market share advantages under the patent linkage system. METHODS: Pairs of originators and their corresponding generics granted the first generic exclusivity from 2015 to 2020 were identified. We categorized generics into first movers and latecomers, described the penetration curves of generics, and estimated the saturated market share of generics, first movers, and latecomers. Volume-based monthly prescriptions were used to describe the generics’ penetration curves. A logistic growth model was adopted to estimate the saturated market shares of generics. RESULTS: We identified 28 pairs of originators and generics, presented penetration curves, and estimated generics market shares. The saturated market share of generics was 30%, and the time to saturation was approximately 33 months. The shapes of penetration varied by nationality, route, and number of generics. The existence of latecomers was associated with the decreased penetration speed over time and decreased market share of generics. However, the first mover market share advantages or latecomers’ disadvantages were consistently observed. CONCLUSION: The generic uptake in South Korea is delayed, limited, and context-dependent. However, first generics’ market share advantage suggests that a period of exclusivity, as part of the patent linkage system, could provide an economic incentive for early generic entrance. Frontiers Media S.A. 2023-08-03 /pmc/articles/PMC10435867/ /pubmed/37601172 http://dx.doi.org/10.3389/fpubh.2023.1120729 Text en Copyright © 2023 Son. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Son, Kyung-Bok
Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title_full Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title_fullStr Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title_full_unstemmed Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title_short Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
title_sort does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435867/
https://www.ncbi.nlm.nih.gov/pubmed/37601172
http://dx.doi.org/10.3389/fpubh.2023.1120729
work_keys_str_mv AT sonkyungbok doesthefirstgenericexclusivitysystemprovideaneconomicincentiveforearlygenericentranceunderthepatentlinkagesystem